Skip to main content
. 2020 Jun 2;20(12):3451–3461. doi: 10.1111/ajt.15961

Table 1.

Cross‐sectional study patient characteristics

  HC (n = 15) DM (n = 12) DN (n = 14) SPKT (n = 35) KTx (n = 13)
Sex, male, n (%) 8 (53%) 6 (50%) 9 (64%) 23 (66%) 4 (31%)
Age (y) 44 ± 10 54 ± 14 44 ± 6 b 48 ± 8 48 ± 10
BMI (kg/m2) 24.8 ± 3.6 23.7 ± 2.6 24.3 ± 2.8 24.1 ± 4.2 24.6 ± 4.8
Systolic blood pressure (mm Hg) 133 ± 13 130 ± 14 141 ± 21 140 ± 23 133 ± 25
Diastolic blood pressure (mm Hg) 83 ± 7 70 ± 9 a 84 ± 10 b 84 ± 13 b 78 ± 12
Haemoglobin (mmol/L) 8.8 ± 0.7 8.4 ± 1.3 7.4 ± 0.7 a , b 8.2 ± 1.1 7.9 ± 1.0
Haematocrit (L/L) 0.42 ± 0.03 0.41 ± 0.05 0.36 ± 0.04 a , b 0.41 ± 0.05 c 0.40 ± 0.04
HbA1c (mmol/mol) 53.7 ± 8.9 63.6 ± 15.6 37.7 ± 8.7 b 67.5 ± 8.7 b
Glucose (mmol/L) 5.2 ± 1.1 12.7 ± 5.1 a 12.5 ± 5.7 a 5.9 ± 2.9 b , c 11.2 ± 5.3 a , d
eGFR (mL/min/1.73 m2) 93 ± 17 71 ± 24 26 ± 17 a 52 ± 19 a , b , c 60 ± 24 a , c
Proteinuria (g/24 h) median (IQR) 0.29 (0.13‐0.53) 0.68 (0.31‐1.16) 0.27 (0.18‐0.81) c 0.21 (0.21‐0.36) c
Smoking, n (%) 0 (0%) 2 (17%) 0 (0%) 3 (9%) 1 (8%)
Antihypertensive drugs, n (%)
ACE inhibitor 6 (50%) 7 (54%) 13 (37%) 6 (46%)
Angiotensin II antagonist 3 (25%) 5 (39%) 8 (23%) 0 (0%) c , d
Calcium antagonist 1 (8%) 6 (46%) b 20 (57%) b 5 (38%)
Diuretic 5 (42%) 6 (46%) 7 (20%) 4 (31%)
Statin, n (%) 6 (50%) 8 (62%) 24 (69%) 5 (38%)
Duration of diabetes (y) 33 ± 9 31 ± 9 28 ± 9 36 ± 9 d
Time since Tx (mo) median (IQR) 45 (19‐102) 21 (9‐74)
Diabetes after SPKT, n (%) 3 (9%)

Abbreviations: BMI, body mass index; DM, diabetes mellitus (eGFR > 35 mL/min/1.73 m2); DN, diabetic nephropathy; HC, healthy controls; KTx, kidney transplantation; SPK, simultaneous pancreas–kidney transplantation; Tx, transplantation (SPKT or KTx).

a

P < .05 vs HC.

b

P < .05 vs DM.

c

P < .05 vs DN.

d

P < .05 vs SPKT.